Bullish Case: VK2735's 17.7% weight loss with 97% maintenance retention is a differentiated dual-agonist profile; $575M raised extends runway into 2029 and removes solvency risk. Oral late-stage start before year-end plus VANQUISH data in 2027 give identifiable catalysts. Helium density shows heavy mass at $24.5-26.5 with residual upside weight to $35+, and calls traded 27% more volume than puts, suggesting accumulation at multi-year lows despite dilution-driven selling.

Bearish Case: The stock has given back nearly the entire September data pop (-40% from $42 peak), showing even 'stellar' data cannot overcome dilution and obesity crowding (Lilly EloraTZP Phase 3, Novo CagriSema approval pending, Hengrui licensing). Bearish risk exceeds bullish by 22% across tenors; front IV ~74% vs Helium's wide band (31-114%) flags binary event risk. Next subQ readouts slip to 2027, and Polymarket deal odds fell to 10%.

Potential Outcomes:

1. 30% — Drift $24-28: oral trial start before year-end is the only near catalyst; falsifiable by filing/IND news.
2. 22% — continued dilution/competition pressure toward $20-22; aligns with 22% excess bearish risk.
3. 20% — oral late-stage start + phase-1 amylin data pop to $28-32.
4. 16% — acquisition bid emerges pre-2027 (Polymarket 10%, Helium pricing higher on 2028-call flow).
5. 12% — safety/timeline shock (-30%+); flagged by 117-148% front OTM call IV and flat term structure.

Trading oracle: cheap long-dated calls (Jan'27 32.5C ~$1.10-1.40) vs selling rich front IV; avoid naked puts.

October 20, 2026